On October 24, 2025, WuXi AppTec Co., Ltd. (WuXi AppTec), a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that its wholly owned subsidiary has entered into a sale and purchase agreement to sell its two subsidiaries, WuXi Clinical Development Services (Shanghai) Co., Ltd. (WuXi Clinical) and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. (WuXi MedKey), to Hillhouse Investment Management (Hillhouse), one of the world’s leading global private asset managers focusing on sectors such as healthcare, manufacturing, green energy, hard technology, and consumer technology. WuXi Clinical and WuXi MedKey are the operating entities of WuXi AppTec engaged in China-based clinical research services.

Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction. The Wilson Sonsini team includes:

Corporate/M&A
Weiheng Chen
Yang Chu
Jie Zhu
Xuchao Dong
Billy Yiu
Yang Liao
Kate Lam

For more information, please see WuXi AppTec’s news release.